IAA18 Antibody

Basic Research Questions

• How to validate IAA18 antibody specificity in auxin signaling studies?

  • Perform co-immunoprecipitation (Co-IP) with known interactors (e.g., ARF6/8 or TPL/TPR proteins) .

  • Use loss-of-function mutants (e.g., iaa18 knockout lines) as negative controls in western blot (WB) or immunofluorescence .

  • Validate via peptide competition assays: pre-incubate the antibody with excess IAA18 epitope peptide to confirm signal loss .

• What are optimal applications for IAA18 antibodies in plant research?

  • Western blotting: Use 1–5 µg/ml purified antibody with protein extracts from auxin-treated tissues (e.g., 1 µM NAA for 2–4 hrs) .

  • Immunolocalization: Fix tissues in 4% paraformaldehyde, permeabilize with 0.1% Triton X-100, and use 5 µg/ml antibody for nuclear/cytosolic signal detection .

  • ELISA: Pair with recombinant IAA18 (e.g., Arabidopsis or Oryza sativa isoforms) at 0.1 µg/ml for quantitative auxin-response assays .

• How to address nonspecific binding in IAA18 immunohistochemistry?

  • Include isotype controls (rabbit IgG) and pre-immune serum to rule out Fc receptor interactions .

  • Optimize blocking buffers: Test 5% BSA vs. goat serum, and add 0.3% Tween-20 to reduce background .

Advanced Methodological Challenges

• Resolving contradictions in IAA18 subcellular localization data

  • IAA18 exhibits nuclear-cytosolic shuttling, influenced by auxin levels and interacting partners (e.g., LSD1) .

  • Method: Combine subcellular fractionation (nuclear vs. cytosolic extracts) with confocal microscopy using GFP-tagged IAA18 under native promoters .

  • Critical controls: Co-stain with nuclear markers (e.g., histone H3) and cytosolic markers (e.g., tubulin) .

• Analyzing IAA18 post-translational modifications (PTMs) in auxin response

  • Ubiquitination assays: Treat transgenic lines (e.g., 35S:IAA18-FLAG) with 10 µM MG132 (proteasome inhibitor) + 10 µM NAA, followed by anti-FLAG immunoprecipitation and anti-ubiquitin WB .

  • Phosphorylation screening: Use Phos-tag™ gels to detect shifts in IAA18 mobility after auxin treatment .

• Interpreting cross-reactivity in non-model species

  • Sequence alignment: Compare IAA18 immunogen sequence (e.g., Arabidopsis residues 120–200) with target species using EMBL-EBI Clustal Omega. Require >85% identity for predicted reactivity .

  • Empirical validation: Test antibody in species with partial alignment (e.g., Oryza sativa IAA18: 73% identity) via WB with recombinant protein .

Table 1: Recommended Antibody Dilutions for IAA18

Table 2: Cross-Reactivity of IAA18 Antibodies

Troubleshooting Data Discrepancies

• Discrepant auxin-response kinetics in IAA18 studies

  • Root: Auxin sensitivity varies with tissue type. For lateral root assays, use 10 nM NAA (24 hrs) with iaa18 mutants .

  • Protein stability: Monitor IAA18 degradation via cycloheximide chase assays (e.g., 1 mM CHX + 10 µM NAA, sampled hourly) .

• Inconsistent Co-IP results with ARF partners

  • ARF binding is auxin-dependent. Include 10 µM IAA in lysis buffers and confirm interactions via bimolecular fluorescence complementation (BiFC) .

  • Test multiple ARFs (e.g., ARF6, ARF8) due to binding specificity differences .

Ethical & Technical Notes

• Antibody lot variability: Always compare new lots using a standardized lysate (e.g., auxin-treated Arabidopsis seedlings) .

• Data reporting: Include raw WB images and quantification of ≥3 biological replicates to support localization/expression claims .